MCIM
NBIX icon

Meadow Creek Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Meadow Creek Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.04M Buy
11,594
+286
+3% +$26.7K 0.02% 479
2019
Q2 		$955K Buy
11,308
+6,644
+142% +$546K 0.02% 503
2019
Q1 		$411K Buy
4,664
+1,100
+31% +$91.9K 0.01% 760
2018
Q4 		$254K Buy
+3,564
New +$341K 0.01% 881

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meadow Creek Investment Management's NBIX Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Neurocrine Biosciences (NBIX) stake by 2.5% in Q3 2019, buying an estimated $26.7K and bringing the position to 11,594 shares worth $1.04M. The position accounts for 0.02% of the portfolio, ranked #479.

Meadow Creek Investment Management first reported a position in NBIX in Q4 2018 and has held it in 4 quarters since. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Meadow Creek Investment Management held 11,594 shares of Neurocrine Biosciences worth $1.04M as of Q3 2019.
  • Meadow Creek Investment Management bought 286 Neurocrine Biosciences shares in Q3 2019, an estimated $26.7K.
  • Neurocrine Biosciences made up 0.02% of Meadow Creek Investment Management's portfolio in Q3 2019, its #479 holding.
  • Meadow Creek Investment Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 4 quarters since.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.